NCT05970575View on ClinicalTrials.gov

Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

July 21, 2025

Study Completion Date

July 21, 2025

Conditions
Traumatic Brain Injury
Interventions
DRUG

NE3107

Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)

Trial Locations (1)

90403

The Regenesis Project, Santa Monica

Sponsors

Collaborators (1)

BioVie Inc.
All Listed Sponsors
collaborator

BioVie Inc.

INDUSTRY

lead

Neurological Associates of West Los Angeles

OTHER